These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Supporting evidence-based rotavirus vaccine introduction decision-making and implementation: Lessons from 8 Gavi-eligible countries. Jennings MC; Sauer M; Manchester C; Soeters HM; Shimp L; Hyde TB; Parashar U; Burgess C; Castro B; Hossein I; Othepa M; Payne DC; Tate JE; Walldorf J; Privor-Dumm L; Richart V; Santosham M; Vaccine; 2024 Jan; 42(1):8-16. PubMed ID: 38042696 [TBL] [Abstract][Full Text] [Related]
29. Rotavirus vaccination in Europe: drivers and barriers. Parez N; Giaquinto C; Du Roure C; Martinon-Torres F; Spoulou V; Van Damme P; Vesikari T Lancet Infect Dis; 2014 May; 14(5):416-25. PubMed ID: 24758998 [TBL] [Abstract][Full Text] [Related]
30. Time to begin a new chapter and expand rotavirus immunization. Anderson EJ Clin Infect Dis; 2014 Oct; 59(7):982-6. PubMed ID: 24944227 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan. Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673 [TBL] [Abstract][Full Text] [Related]
32. A review of rotavirus infection in and vaccination of human immunodeficiency virus-infected children. Steele AD; Cunliffe N; Tumbo J; Madhi SA; De Vos B; Bouckenooghe A J Infect Dis; 2009 Nov; 200 Suppl 1():S57-62. PubMed ID: 19817615 [TBL] [Abstract][Full Text] [Related]
33. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries. Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590 [TBL] [Abstract][Full Text] [Related]
34. Economic evaluations of rotavirus immunization for developing countries: a review of the literature. Tu HA; Woerdenbag HJ; Kane S; Rozenbaum MH; Li SC; Postma MJ Expert Rev Vaccines; 2011 Jul; 10(7):1037-51. PubMed ID: 21806398 [TBL] [Abstract][Full Text] [Related]
35. Rotavirus vaccination in central Europe. Mészner Z; Anca I; André F; Chlibek R; Čižman M; Grzesiowski P; Mangarov A; Pokorn M; Prymula R; Richter D; Salman N; Šimurka P; Tamm E; Tešović G; Urbancikova I; Usonis V; Zavadska D; J Pediatr Gastroenterol Nutr; 2013 Jun; 56(6):586-96. PubMed ID: 23708638 [TBL] [Abstract][Full Text] [Related]
36. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines. Widdowson MA; Steele D; Vojdani J; Wecker J; Parashar U J Infect Dis; 2009 Nov; 200 Suppl 1():S1-8. PubMed ID: 19817589 [TBL] [Abstract][Full Text] [Related]
37. [Recommendations for the use of rotavirus vaccines in industrialized countries]. Franco E Ig Sanita Pubbl; 2006; 62(6):697-700. PubMed ID: 17256023 [TBL] [Abstract][Full Text] [Related]
38. Estimating the costs of implementing the rotavirus vaccine in the national immunisation programme: the case of Malawi. Madsen LB; Ustrup M; Hansen KS; Nyasulu PS; Bygbjerg IC; Konradsen F Trop Med Int Health; 2014 Feb; 19(2):177-85. PubMed ID: 24314006 [TBL] [Abstract][Full Text] [Related]
39. Rotavirus vaccination within the South African Expanded Programme on Immunisation. Seheri LM; Page NA; Mawela MP; Mphahlele MJ; Steele AD Vaccine; 2012 Sep; 30 Suppl 3():C14-20. PubMed ID: 22939015 [TBL] [Abstract][Full Text] [Related]
40. [Vaccination against chickenpox, shingles and rotavirus-infection]. Hartwig NG; Rümke HC; Visser HK Ned Tijdschr Geneeskd; 2009; 153():A913. PubMed ID: 19900343 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]